{"id":742770,"date":"2023-03-27T08:19:17","date_gmt":"2023-03-27T12:19:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/"},"modified":"2023-03-27T08:19:17","modified_gmt":"2023-03-27T12:19:17","slug":"terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/","title":{"rendered":"Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology"},"content":{"rendered":"

\nExperienced Leader Brings Extensive Clinical Development and Medical Affairs Expertise in Oncology
\n<\/h2>\n
\n

FOSTER CITY, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (\u201cTerns\u201d or the \u201cCompany\u201d) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced the appointment of Emil Kuriakose, M.D. as chief medical officer of Terns oncology, effective May 1, 2023. Dr. Kuriakose brings more than a decade of clinical development and medical affairs experience spanning early through late phase development in several oncology indications at Novartis and Calithera Biosciences, where he most recently was serving as chief medical officer. After Dr. Kuriakose commences his employment at Terns, Kerry Russell, M.D., will assume the role of chief medical officer of Terns metabolic with responsibility for Terns\u2019 NASH and obesity programs.<\/p>\n

\u201cWe are delighted to welcome Emil to the Terns leadership team.\u00a0 Emil\u2019s deep relationships and expertise in the clinical development of new cancer treatments, combined with his extensive experience treating people with cancer, will be of great benefit as we advance our TERN-701 program in chronic myeloid leukemia (CML) into clinical development in the United States and continue to build our oncology development team,\u201d said Sen Sundaram, chief executive officer at Terns. \u201cAs chief medical officer of Terns metabolic, Kerry \u2018s experience will continue to benefit our metabolic franchise in obesity and NASH where we expect to continue to build on our leading positions.\u201d<\/p>\n

\u201cI am pleased to join Terns at this key juncture in the clinical development of TERN-701 to treat CML.\u00a0 There remains a tremendously high unmet need for therapeutic options for people living with CML, as current standard of care treatments are often switched due to safety concerns or intolerance. Allosteric TKIs like TERN-701, have shown significant improvements over active-site TKIs on the market today. TERN-701 represents an exciting option for people with CML. I look forward to leveraging my experience to advance TERN-701 for the treatment of CML and expand Terns\u2019 oncology franchise,\u201d commented Dr. Kuriakose.<\/p>\n

Dr. Kuriakose joins Terns with more than a decade of biopharmaceutical industry experience, leading clinical development strategy and execution of therapeutics across multiple indications. In his most recent role as chief medical officer at Calithera Biosciences, Dr. Kuriakose led the transition of two mid-stage clinical programs with subsequent rapid initiation of two phase 2 studies. Previously, Dr. Kuriakose served as global clinical program lead at Novartis Institutes for BioMedical Research (NIBR), where he was the global head of early development for MDM2 inhibitor (targeted therapy) and adenosine inhibitor programs in solid and hematologic malignancies. In this role, he was responsible for the development and execution of the clinical development for new oncology agents from the candidate selection process to clinical proof-of-concept stage and integrated development plan including design and execution of phase 1 and 2 clinical trials of novel compounds in the oncology and immuno-oncology portfolio. \u00a0Before that, he served as medical director at Novartis Oncology, where he led a cross-functional team in the design and execution of trials exploring novel immune-oncology and targeted therapy combinations and oversaw late-stage clinical development, strategy, and medical affairs program for farydak (HDACi), sonidegib (Hh inhibitor), and afuresertib (AKTi) in the United States.\u00a0<\/p>\n

Earlier in his career, Dr. Kuriakose served as a hematology\/oncology fellow at Weill Cornell Medical College and as a research fellow at Memorial Sloan Kettering Cancer Center. He completed his residency at UT Southwestern Medical Center, where he also served as an attending physician. Dr. Kuriakose earned an M.D. from SUNY Stony Brook University School of Medicine and a B.S. in Neuroscience from New York University.<\/p>\n

\n About Terns Pharmaceuticals<\/strong>
\n
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, NASH and obesity. Terns\u2019 pipeline includes two clinical stage development programs including an allosteric BCR-ABL inhibitor and a THR-\u03b2 agonist (+\/- an FXR agonist), and preclinical small-molecule GLP-1 receptor agonist and GIPR modulator programs. For more information, please visit:\u00a0www.ternspharma.com<\/a>.<\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the \u201cCompany,\u201d \u201cwe,\u201d \u201cus,\u201d or \u201cour\u201d) within the meaning of the federal securities laws, including those related to the Company\u2019s expectations of timing and potential results of the Company\u2019s clinical trials and other development activities; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company\u2019s small-molecule product candidates; the potential for the mechanisms of action of the Company\u2019s product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company\u2019s product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company\u2019s clinical trials; the Company\u2019s clinical development plans and activities; the Company\u2019s expectations regarding the profile of its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company\u2019s plans for and ability to continue to execute on its current development strategy, including potential combinations involving multiple product candidates; the impact of new legislation and regulatory developments on the Company\u2019s plans for its product candidates, such as the effect of the Inflation Reduction Act of 2022; and the Company\u2019s expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release, including statements regarding the Company\u2019s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as \u201caim,\u201d \u201canticipate,\u201d \u201cassume,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cdesign,\u201d \u201cdue,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cobjective,\u201d \u201cplan,\u201d \u201cpositioned,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company\u2019s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company\u2019s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company\u2019s actual results, please refer to the risk factors identified in the Company\u2019s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2021 and its Quarterly Report on Form 10-Q for the periods ended March 31, 2022, June 30, 2022 and September 30, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.<\/p>\n

\n Contacts for Terns<\/strong>\n <\/p>\n

\n Investors<\/strong>
\n
Justin Ng
investors@ternspharma.com<\/a><\/p>\n

\n Media<\/strong>
\n
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com<\/a><\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Experienced Leader Brings Extensive Clinical Development and Medical Affairs Expertise in Oncology FOSTER CITY, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (\u201cTerns\u201d or the \u201cCompany\u201d) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced the appointment of Emil Kuriakose, M.D. as chief medical officer of Terns oncology, effective May 1, 2023. Dr. Kuriakose brings more than a decade of clinical development and medical affairs experience spanning early through late phase development in several oncology indications at Novartis and Calithera Biosciences, where he most recently was serving as chief medical officer. After Dr. Kuriakose commences his employment at Terns, Kerry Russell, … <\/p>\n

Continue reading “Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-742770","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTerns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Experienced Leader Brings Extensive Clinical Development and Medical Affairs Expertise in Oncology FOSTER CITY, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (\u201cTerns\u201d or the \u201cCompany\u201d) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced the appointment of Emil Kuriakose, M.D. as chief medical officer of Terns oncology, effective May 1, 2023. Dr. Kuriakose brings more than a decade of clinical development and medical affairs experience spanning early through late phase development in several oncology indications at Novartis and Calithera Biosciences, where he most recently was serving as chief medical officer. After Dr. Kuriakose commences his employment at Terns, Kerry Russell, … Continue reading "Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-27T12:19:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTY5NSM1NDkyMTQ5IzIyMDQxNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology\",\"datePublished\":\"2023-03-27T12:19:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\\\/\"},\"wordCount\":1241,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NTY5NSM1NDkyMTQ5IzIyMDQxNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\\\/\",\"name\":\"Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NTY5NSM1NDkyMTQ5IzIyMDQxNjM=\",\"datePublished\":\"2023-03-27T12:19:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NTY5NSM1NDkyMTQ5IzIyMDQxNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NTY5NSM1NDkyMTQ5IzIyMDQxNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/","og_locale":"en_US","og_type":"article","og_title":"Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology - Market Newsdesk","og_description":"Experienced Leader Brings Extensive Clinical Development and Medical Affairs Expertise in Oncology FOSTER CITY, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (\u201cTerns\u201d or the \u201cCompany\u201d) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced the appointment of Emil Kuriakose, M.D. as chief medical officer of Terns oncology, effective May 1, 2023. Dr. Kuriakose brings more than a decade of clinical development and medical affairs experience spanning early through late phase development in several oncology indications at Novartis and Calithera Biosciences, where he most recently was serving as chief medical officer. After Dr. Kuriakose commences his employment at Terns, Kerry Russell, … Continue reading \"Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-27T12:19:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTY5NSM1NDkyMTQ5IzIyMDQxNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology","datePublished":"2023-03-27T12:19:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/"},"wordCount":1241,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTY5NSM1NDkyMTQ5IzIyMDQxNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/","name":"Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTY5NSM1NDkyMTQ5IzIyMDQxNjM=","datePublished":"2023-03-27T12:19:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTY5NSM1NDkyMTQ5IzIyMDQxNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTY5NSM1NDkyMTQ5IzIyMDQxNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-appoints-emil-kuriakose-m-d-as-chief-medical-officer-of-terns-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=742770"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742770\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=742770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=742770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=742770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}